Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022006386 - ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2

Publication Number WO/2022/006386
Publication Date 06.01.2022
International Application No. PCT/US2021/040071
International Filing Date 01.07.2021
IPC
C07D 403/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 403/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
Applicants
  • ENLIVEN THERAPEUTICS, INC. [US]/[US]
Inventors
  • LYSSIKATOS, Joseph P.
Agents
  • CHOING, Stephanie
  • ZHOU, Jie
Priority Data
63/047,77602.07.2020US
63/160,60612.03.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
(FR) DÉRIVÉS DE QUINAZOLINE ALCYNE SERVANT D'INHIBITEURS D'ERBB2
Abstract
(EN) The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
(FR) La présente divulgation concerne d'une manière générale des composés et des compositions de ceux-ci pour l'inhibition d'ErbB2, comprenant des formes mutantes d'ErbB2, en particulier ceux présentant une mutation Exon 20, des procédés de préparation desdits composés et desdites compositions, et leur utilisation dans le traitement ou la prophylaxie de divers cancers, tels que du poumon, le gliome, de la peau, du cou et de la tête, de la glande salivaire, du sein, de l’œsophage, du foie, de l'estomac (gastrique), de l'utérus, du col de l'utérus, du tractus biliaire, le cancer du pancréas, le cancer colorectal, le cancer des reins, de la vessie ou le cancer de la prostate.
Latest bibliographic data on file with the International Bureau